Kathleen Mulvaney

Our lab focuses on understanding cancer dependencies--why cancers rely on certain genes and proteins to survive, and how we can drug them to make new therapies for cancer patients. Several projects in the lab focus on understanding how one cancer dependency, the methyltransferase PRMT5, is regulated in normal biology and cancer. We aim to determine effective sites of PRMT5 inhibition, effective combination therapies with PRMT5, PRMT5 regulation of subcellular processes such as splicing and translation, and PRMT5 crosstalk with cancer immunology. Other projects in the lab are studying efflux transporters and identification of new cancer dependencies. To do so, we use CRISPR screening and proteomics, followed by traditional cell biology, biochemistry, and molecular biology techniques.